What is Crohn’s Disease?
Crohn’s Disease is a type of inflammatory bowel disease (IBD). It is an inflammatory condition of the gastrointestinal tract, which most commonly affects the end of the small bowel (the ileum), the beginning of the colon, and any part of the gastrointestinal (GI) tract from the mouth to the anus.
How many people are affected by Crohn’s Disease?
Crohn’s Disease Treatment
The standardized approved evidence-based therapies for the Crohn’s Disease treatment include infliximab (Remicade; Janssen Biotech), adalimumab (Humira; AbbVie), certolizumab Pegol (Cimzia; UCB), natalizumab (Tysabri; Biogen), vedolizumab (Entyvio; Millennium Pharmaceuticals), and Ustekinumab (Stelara; Janssen Biotech). These therapies have been approved for moderate to severe Crohn’s Disease.
Request for free sample pages @ Crohn’s Disease Market trends
How will Crohn’s Disease Market change in upcoming years?
The growth of the Crohn’s Disease market include increased understanding of the disease, introduction of novel therapies in the Crohn’s Disease market, and other innovative treatment options to overcome the limitation of the current Crohn’s Disease treatment regimen and improved patient-of-care.
Expected launch of emerging therapies such as AbbVie’s risankizumab, Genentech’s etrolizumab, and other therapies shall increase the market size of Crohn’s Disease.
Crohn’s Disease Emerging Therapies
The launch of emerging therapies such as Filgotinib (Gilead Sciences), Risankizumab (Abbvie), Etrolizumab (Genetech), PDA-001 (Celularity) and other compelling treatments are expected to increase the Crohn’s Disease market size in upcoming years.
Key players such as Gilead Sciences, Celgene Corporation, Abbvie, Genetech, and many others are involved in developing therapies for Crohn’s Disease.
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/